Schizophrenia News and Research

Latest Schizophrenia News and Research

Schizophrenia cognition tool promising in bipolar disorder patients

The Brief Assessment of Cognition in Schizophrenia may be an appropriate tool for measuring cognition in elderly patients with bipolar disorder, a pilot study suggests.

22 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

People who are less patient tend to move eyes with greater speed, say researchers

Using a simple study of eye movements, Johns Hopkins scientists report evidence that people who are less patient tend to move their eyes with greater speed. The findings, the researchers say, suggest that the weight people give to the passage of time may be a trait consistently used throughout their brains, affecting the speed with which they make movements, as well as the way they make certain decisions.

22 Jan 2014

Italian biochemist receives Louis-Jeantet Prize for Medicine for the year 2014

The 2014 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the Italian biochemist Elena Conti, Director of the Department of Structural Cell Biology at the Max-Planck Institute of Biochemistry in Munich (Germany) and to Denis Le Bihan, the French medical doctor, physicist and Director of NeuroSpin, an institute at the French Nuclear and Renewable Energy Commission (CEA) at Saclay near Paris.

22 Jan 2014

Experiencing family death in childhood linked with increased risk of psychosis

Experiencing a family death in childhood is associated with a small but significant increase in risk of psychosis, suggests a paper published today on bmj.com.

21 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Psychosis risk following childhood abuse not down to genetics

Familial risk for psychosis does not account for the association between abuse during childhood and the later development of schizophrenia, a study suggests.

20 Jan 2014

Research shows how architecture of brain shapes its functioning

The structure of the human brain is complex, reminiscent of a circuit diagram with countless connections. But what role does this architecture play in the functioning of the brain?

20 Jan 2014

CSHL professor identifies two proteins that control structure of chandelier cells

Chandelier cells are neurons that use their unique shape to act like master circuit breakers in the brain's cerebral cortex. These cells have dozens, often hundreds, of branching axonal projections - output channels from the cell body of the neuron - that lend the full structure of a chandelier-like appearance.

17 Jan 2014

Severe infection associated with increased risk for psychotic illness

Hospital admission for infections in childhood is associated with an increased risk for being diagnosed with nonaffective psychosis later in life, research indicates.

16 Jan 2014

More evidence for glutamate dysregulation in schizophrenia

Levels of glutamine, but not glutamate, are elevated in the dorsal anterior cingulate of patients with established schizophrenia, say researchers.

15 Jan 2014

New programme to reduce risk of type 2 diabetes in people with schizophrenia

A group of researchers, led by Professor Richard Holt at the University of Southampton, are to investigate whether people with schizophrenia or first episode psychosis are able to reduce their weight through a structured education programme.

14 Jan 2014

Cortical thickness changes may contribute to early schizophrenia

Altered cortical thickness is related to the severity of positive symptoms in patients with first-episode schizophrenia, but not to the duration of untreated illness, report researchers.

14 Jan 2014

Distinct developmental trajectories for bipolar disorder and schizophrenia

Early diagnoses given to patients with a final diagnosis of bipolar disorder are markedly different from those given to patients with schizophrenia, a study shows.

14 Jan 2014

Early psychoeducation helps schizophrenia carers cope

Psychoeducation should be routinely offered to family members of schizophrenia patients as early as possible following diagnosis, findings from a mixed-method systematic review indicate.

10 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

Longer reads: Hospice drains Medicare; false Obamacare 'horror stories;' growing up without vaccines

Hospice patients are expected to die: The treatment focuses on providing comfort to the terminally ill, not finding a cure. To enroll a patient, two doctors certify a life expectancy of six months or less. But over the past decade, the number of "hospice survivors" in the United States has risen dramatically, in part because hospice companies earn more by recruiting patients who aren't actually dying, a Washington Post investigation has found. Healthier patients are more profitable because they require fewer visits and stay enrolled longer (Peter Whoriskey and Dan Keating, 12/26).

9 Jan 2014